Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

CritiTech conducts research and development into the production and application of fine-particle compounds. It has expanded its operations to include applications in fine particle api production, coatings, and internal product development. Their unique particle engineering innovation and expertise as well as their demonstrated experience in delivering high-quality, on-time results.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Lisen Imprinting Diagnostic Technology (Wuxi) Co., Ltd., established on 2016-10-21, Business scope includes probes,Kit experimental material development;Diagnostic Technology R&D;Technology development in the field of biotechnology,technical consulting,Technical Services and Technology Transfer;Development of diagnostic reagents;biological reagent,Sales of Class I Medical Devices;Production of Class I Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Researches treatments for cancer and develops pharmaceuticals related to cancer treatments

Creo Medical Ltd. develops, manufactures and commercializes medical device technologies. It offers CROMA system, an electrosurgical unit that delivers bipolar radiofrequency power for the purpose of cutting, and microwave power for the purpose of coagulating tissue to staunch bleeding vessels. The firm also offers RS2 instrument, a retractable injection needle for tissue lift and irrigation. The company was founded by Christopher Paul Hancock and Steven Morris in 2003 and is headquartered in Chepstow, the United Kingdom.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Sirtex Medical Ltd. manufactures, and distributes liver cancer treatments. It operates through the following geographical segments: Asia Pacific, Americas, and Europe, Middle East, and Africa. It offers targeted radiation therapy known as SIR Spheres Y-90 resin microspheres. The company was founded in 1997 and is headquartered in St Leonards, Australia.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Exact Sciences Development Co. LLC, part of EXACT Sciences Corp., is an American company. The firm engages in research and development diagnostic test for cancer.

OncoPlexDx is a CLIA-certified cancer diagnostics laboratory in Rockville, MD that provides clinical proteomics for patient care. By quantitating proteins, It provide information that helps physicians choose targeted therapies and avoid therapies that won’t work.

American Marketing & Sales, Inc. manufactures servingware, partyware and food service products. Its products include rim and deluxe platters, utensils, bowls and lids, and pectangular tryas and oval platters. The firm offers finished food packaging products. The company was founded in 1999 and is headquartered in Middletown, NY.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Aerwave Medical develops an alternative to traditional medications used to treat COPD and asthma. Its interventional approach provides improvement for patients who are refractory to drug therapy, enabling healthcare institutions to address a significant unmet medical need. The company was founded in 2020 and is based in New York, New York.